ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) released its quarterly earnings results on Monday. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.10, Zacks reports.
ESSA Pharma Stock Performance
Shares of ESSA Pharma stock traded down $0.10 during trading hours on Tuesday, hitting $4.53. The company’s stock had a trading volume of 28,170 shares, compared to its average volume of 95,495. The firm has a fifty day moving average of $5.30 and a 200-day moving average of $7.08. The stock has a market cap of $200.95 million, a price-to-earnings ratio of -7.29 and a beta of 1.82. ESSA Pharma has a twelve month low of $2.58 and a twelve month high of $11.67.
Analyst Upgrades and Downgrades
Separately, Oppenheimer reiterated an “outperform” rating and issued a $17.00 price objective on shares of ESSA Pharma in a report on Thursday, May 16th.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
See Also
- Five stocks we like better than ESSA Pharma
- Learn Technical Analysis Skills to Master the Stock Market
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- What is Put Option Volume?
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- How Can Investors Benefit From After-Hours Trading
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
